These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 30661647)
1. Retuning the immune system in myelodysplastic syndromes: from immunomodulatory approaches to vaccination strategies and non myeloablative hemopoietic cell transplant. Fozza C Crit Rev Oncol Hematol; 2019 Jan; 133():112-119. PubMed ID: 30661647 [TBL] [Abstract][Full Text] [Related]
2. Feasible outcomes of T cell-replete haploidentical stem cell transplantation with reduced-intensity conditioning in patients with myelodysplastic syndrome. Shin SH; Kim JH; Jeon YW; Yoon JH; Yahng SA; Lee SE; Choi YS; Kim DY; Lee JH; Lee S; Kim HJ; Min CK; Lee JW; Lee KH; Min WS; Kim YJ; Lee JH Biol Blood Marrow Transplant; 2015 Feb; 21(2):342-9. PubMed ID: 25459640 [TBL] [Abstract][Full Text] [Related]
3. Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %-a feasibility study. Choi EJ; Lee JH; Lee JH; Kim DY; Park HS; Seol M; Lee YS; Kang YA; Jeon M; Lee KH Ann Hematol; 2016 Jun; 95(7):1151-61. PubMed ID: 27106699 [TBL] [Abstract][Full Text] [Related]
4. Antithymocyte globulin improves the survival of patients with myelodysplastic syndrome undergoing HLA-matched unrelated donor and haplo-identical donor transplants. Wang H; Liu H; Zhou JY; Zhang TT; Jin S; Zhang X; Chen SN; Li WY; Xu Y; Miao M; Wu DP Sci Rep; 2017 Mar; 7():43488. PubMed ID: 28262717 [TBL] [Abstract][Full Text] [Related]
5. The immune landscape of myelodysplastic syndromes. Fozza C; Crobu V; Isoni MA; Dore F Crit Rev Oncol Hematol; 2016 Nov; 107():90-99. PubMed ID: 27823655 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden. Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940 [TBL] [Abstract][Full Text] [Related]
8. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. Valcárcel D; Martino R Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468 [TBL] [Abstract][Full Text] [Related]
9. Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. Duléry R; Mohty M; Duhamel A; Robin M; Beguin Y; Michallet M; Vigouroux S; Lioure B; Garnier A; El Cheikh J; Bulabois CE; Huynh A; Bay JO; Daguindau E; Ceballos P; Clément L; Dauriac C; Maillard N; Legrand F; Cornillon J; Guillerm G; François S; Lapusan S; Chevallier P; Damaj G; Yakoub-Agha I Biol Blood Marrow Transplant; 2014 May; 20(5):646-54. PubMed ID: 24462982 [TBL] [Abstract][Full Text] [Related]
12. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review]. Zhang Z; Li X Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102 [TBL] [Abstract][Full Text] [Related]
15. Which Patients Should Undergo Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes, and When Should We Do It? Oran B Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S43-9. PubMed ID: 26297277 [TBL] [Abstract][Full Text] [Related]
16. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience. Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902 [TBL] [Abstract][Full Text] [Related]
17. The Yin and Yang of myelodysplastic syndromes and autoimmunity: The paradox of autoimmune disorders responding to therapies specific for MDS. Fozza C; La Nasa G; Caocci G Crit Rev Oncol Hematol; 2019 Oct; 142():51-57. PubMed ID: 31376677 [TBL] [Abstract][Full Text] [Related]
18. Allogeneic Hematopoietic Cell Transplantation Is Safe and Effective Treatment in Patients with Myelodysplastic Syndromes Seventy Years and Older. Mukherjee S Biol Blood Marrow Transplant; 2017 Jan; 23(1):1-2. PubMed ID: 27865911 [No Abstract] [Full Text] [Related]
19. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes? Fozza C; Longinotti M Eur J Haematol; 2012 May; 88(5):380-7. PubMed ID: 22296182 [TBL] [Abstract][Full Text] [Related]
20. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Scott BL; Sandmaier BM; Storer B; Maris MB; Sorror ML; Maloney DG; Chauncey TR; Storb R; Deeg HJ Leukemia; 2006 Jan; 20(1):128-35. PubMed ID: 16270037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]